SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Clarke Philip)
 

Sökning: WFRF:(Clarke Philip) > (2020-2023) > An Economic Model f...

  • Schilling, ChrisUniversity of Melbourne (författare)

An Economic Model for Estimating Trial Costs with an Application to Placebo Surgery Trials

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2022-12-28
  • Springer Science and Business Media LLC,2023

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:df66ec96-a467-492e-93e7-593567a0b4ab
  • https://lup.lub.lu.se/record/df66ec96-a467-492e-93e7-593567a0b4abURI
  • https://doi.org/10.1007/s40258-022-00775-4DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background and Objective: Waste in clinical trials remains rife. We developed an economic model to predict the cost of trials based on input costs, duration, power, number of sites, recruitment eligibility and consenting rates. Methods: We parameterised the model for three proxy placebo-controlled surgical trials using data from a systematic review, a bespoke cost survey, and from the literature. We used the model to compare target and actual trial performance for (i) a trial that was completed on time but with more sites, (ii) a trial that completed after a time extension, and (iii) an incomplete trial. Results: Successful trials more accurately anticipated the true recruitment rate that they achieved and those that overestimated this were most likely to fail. The costs of overestimating recruitment rates were dramatic: all proxy trials had significantly higher costs than planned, with additional funding of at least AUD$600,000 (50% above budget) required for trials that completed after adding more sites or more time, and over AUD$2 million (260% above budget) for incomplete trials. Conclusions: This model shows the trade-offs between time and cost, or both, when recruitment is lower than anticipated. Greater consideration is needed to improve trial planning, reviewing, and funding of these trials to avoid costly overruns and incomplete trials.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Tew, MichelleUniversity of Melbourne (författare)
  • Bunzli, SamanthaUniversity of Melbourne (författare)
  • Shadbolt, CadeUniversity of Melbourne (författare)
  • Lohmander, L. StefanLund University,Lunds universitet,Ortopedi, Lund,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund OsteoArthritis Division - Nedbrytning av ledbrosk: en biologisk process som leder till artros,Forskargrupper vid Lunds universitet,Orthopaedics (Lund),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund OsteoArthritis Division - Molecular marker research group,Lund University Research Groups(Swepub:lu)ort-slo (författare)
  • Balogh, Zsolt J.University of Newcastle (författare)
  • Paolucci, FrancescoUniversity of Bologna,University of Newcastle (författare)
  • Choong, Peter F.University of Melbourne,St. Vincent's Hospital, Melbourne (författare)
  • Dowsey, Michelle M.University of Melbourne,St. Vincent's Hospital, Melbourne (författare)
  • Clarke, PhilipUniversity of Melbourne,University of Oxford (författare)
  • University of MelbourneOrtopedi, Lund (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Applied Health Economics and Health Policy: Springer Science and Business Media LLC21:2, s. 263-2731175-56521179-1896

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy